HUTCHMED’s FRUZAQLA approved or launched in 41 countries
HUTCHMED reported its 2026 interim results, showing total revenue broadly unchanged at $278.3 million and net income of $15.9 million. Oncology product in-market sales increased significantly, with FRUZAQLA global sales reaching $185.4 million due to strong ex-US growth and launches/approvals in 41 countries. The …